Evergreen Youth Secrets
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
No Result
View All Result
Evergreen Youth Secrets
No Result
View All Result
Home Health Care

FDA will reconsider decision barring copycat versions of Lilly weight loss drug

by
October 14, 2024
in Health Care
0
FDA will reconsider decision barring copycat versions of Lilly weight loss drug

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions. 

A federal court in Texas on Friday granted the FDA’s unopposed motion to stay litigation over the drug’s removal from shortage.  

In a court filing late Friday, the FDA said it wouldn’t pursue regulatory action against the plaintiff compounding pharmacies for making copies of the drugs while it reconsiders the decision. 

The FDA’s motion marked a significant reversal for the agency, which was sued last week by compounding pharmacies and a trade organization representing compounding pharmacies after removing tirzepatide from the shortage list. 

At the time, the agency said removing the drug meant compounding pharmacies would no longer be legally allowed to continue making and dispensing their own versions.  

In the lawsuit, the Outsourcing Facilities Association claimed the drug was still in short supply, and that the agency’s decision was “reckless and arbitrary.” The group asked a federal court in Texas to issue a 14-day temporary restraining order that would prevent the FDA from taking action against any of the plaintiffs for continuing to make copies of the drug.  

Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity.  

In a statement to The Hill, a spokesperson for Lilly said all doses of Mounjaro and Zepbound are available and reiterated the branded drug industry’s view that compounded versions are risky for patients. 

“All doses of Lilly’s FDA-approved medicines are available and it is important that patients not be exposed to the risks in taking untested, unapproved knockoffs,” the spokesperson said.  

“FDA has rightly and repeatedly expressed concerns with unapproved GLP-1 drugs used for weight loss, and that such drugs are risky for patients, as unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are marketed.”   

Compounded anti-obesity drugs are sold at vastly lower prices than the branded versions and can give patients needed access to drugs that are in shortage. The lawsuit argued the FDA was taking away that access.  

In the motion, the FDA asked the court to pause the lawsuit and remand the case back to the agency, which would allow it to “reevaluate the decision in light of Plaintiffs’ challenges to it.”  

The agency said it would not take action against the compounders while it reconsiders, “which is effectively the relief that plaintiffs sought.” 

The agency asked the plaintiffs to “submit additional information regarding tirzepatide’s availability” while it reconsiders. 

U.S. District Judge Mark Pittman in Fort Worth, Texas, granted the motion and put the lawsuit on hold. A joint status report is due Nov. 21. 

The FDA said its enforcement discretion will extend from the date of the order to two weeks beyond its reconsideration of the decision.  

In a statement, Outsourcing Facilities Association chair Lee Rosebush called the move a “fair resolution” and said the group is “greatly relieved, for our members and the many patients that they serve, that the FDA has agreed to reconsider its decision.”  

He added that “should the FDA repeat its removal decision when a shortage still genuinely exists, we will return to court.” 

Previous Post

Human sense of smell is faster than previously thought, new study suggests

Next Post

Democratic groups launch $2.5M ad buy attacking Republicans over reproductive access

Next Post
Democratic groups launch $2.5M ad buy attacking Republicans over reproductive access

Democratic groups launch $2.5M ad buy attacking Republicans over reproductive access

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    Popular News

    Trump demands drugmakers ‘justify’ COVID treatment success

    Trump demands drugmakers ‘justify’ COVID treatment success

    September 1, 2025
    Former CDC directors sound alarm over Kennedy’s agency shake-up

    Former CDC directors sound alarm over Kennedy’s agency shake-up

    September 1, 2025
    Candida auris: Study reveals who is most vulnerable to deadly fungus infection

    Candida auris: Study reveals who is most vulnerable to deadly fungus infection

    September 1, 2025

    Trending

    Trump’s new CDC pick: A ‘data-driven’ government insider

    Trump’s new CDC pick: A ‘data-driven’ government insider

    May 1, 2025
    India confirms first HMPV cases amid surge in China

    India confirms first HMPV cases amid surge in China

    January 7, 2025
    Novo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy

    Novo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy

    April 29, 2025
    ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices

    ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices

    September 25, 2024

    Recent News

    Trump demands drugmakers ‘justify’ COVID treatment success

    Trump demands drugmakers ‘justify’ COVID treatment success

    September 1, 2025
    Former CDC directors sound alarm over Kennedy’s agency shake-up

    Former CDC directors sound alarm over Kennedy’s agency shake-up

    September 1, 2025

    Popular News

    • Trump demands drugmakers ‘justify’ COVID treatment success
    • Former CDC directors sound alarm over Kennedy’s agency shake-up

    About Evergreen Youth Secrets

    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.

    No Result
    View All Result
    • Health News
    • Health Care
    • Staying Healthy
    • Beauty Advices

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.